Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 5/20 | 0.41 |
| ▸ | AXL | P30530 | 2/20 | 0.41 |
| ▸ | MST1R | Q04912 | 4/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | RET | P07949 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.40 |
| ▸ | PRKACA | P17612 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | ABL2 | P42684 | 1/20 | 0.40 |
| ▸ | FRK | P42685 | 1/20 | 0.40 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721541 | 0.87 | MET (0.50) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL16366161 | 0.86 | LMNA (0.41) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL15506038 | 0.85 | GLA (0.43) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL21383502 | 0.85 | MET (0.43) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL21385290 | 0.84 | MEN1 (0.45) | MET | |
| SCHEMBL22234532 | 0.80 | MET (0.43) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL21383448 | 0.78 | AXL (0.43) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL18186587 | 0.77 | MET (0.53) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL14705756 | 0.77 | MET (0.50) | METAXLMST1RPLK4ABL1 | |
| SCHEMBL23071634 | 0.76 | MET (0.52) | METAXLMST1RPLK4ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3762392-B1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO LTD (KR) | 2024-05-15 | — | — | EP | disclosed |
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | WELLMARKER BIO CO., LTD. (KR) | 2022-09-20 | — | — | US | disclosed |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO, LTD. (KR) | 2022-09-15 | — | — | US | disclosed |
| CN-111295386-B | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2022-09-06 | — | — | CN | disclosed |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2021-10-14 | — | — | US | disclosed |
| EP-3762392-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Wellmarker Bio Co., Ltd. (KR) | 2021-01-13 | — | — | EP | disclosed |
| CN-111295386-A | Thienopyridine derivatives and pharmaceutical compositions containing the same | 伟迈可生物有限公司 | 2020-06-16 | — | — | CN | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019182274-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | WELLMARKER BIO CO., LTD. (KR) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11447500-B2 | Thienopyridine derivatives and pharmaceutical composition comprising same | MAP4K5, MAP4K2, MAP3K9 | CYP1A2 1373/4885CYP2C9 868/4885CYP2C19 563/4885 |
| US-20210317133-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | MAP4K5, MAP4K2, MAP3K9 | CYP1A2 1373/4885CYP2C9 868/4885CYP2C19 563/4885 |
| US-20220288043-A1 | THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | PRKACA, MAP4K5, MAPKAPK5 | CYP1A2 2343/4885CYP2C9 1532/4885CYP2C19 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.